Introduction

Anastomotic leakage after surgery for colorectal cancer is a serious complication, causing an increased morbidity rate and mortality rate1,2.

There is a debate and conflicting evidence on whether non-steroidal anti-inflammatory drugs (NSAIDs) increase the risk of leak3,4. NSAIDs act by inhibiting cyclooxygenase (COX) enzymes, which can be subdivided into isoenzymes COX-1 and COX-2. In a seminal study by Reisinger et al.5, knocking out the COX-2 gene resulted in an increase of colonic anastomotic leaks in mice. In a complementary cohort of colorectal cancer patients5, an increased frequency of anastomotic leaks was demonstrated among those homozygous for the COX-2 gene promoter mutation −765G > C (also known as rs20417). This finding could potentially be translated into clinical use following external validation.

Biological effects might not only be present among those homozygous for the minor allele of −765C/C. For example, the heterozygous state of −765G/C has been associated with a decreased postoperative inflammatory response6.

The present study aimed to evaluate the prevalence of the polymorphism 765G > C in a Swedish cohort of colorectal cancer patients, and its association with postoperative peritoneal infection.

Methods

This is a retrospective matched case-control study on colorectal cancer patients treated with resection with a curative intent and a primary anastomosis between 1 January 2010 and 31 December 2015, at the Uppsala or Umeå University Hospitals. The regional ethical review board at Umeå University and the national ethical review board provided ethical approval (dnr 2015/425-31, dnr 2019-05594 and dnr 2021-02568). The included patients consented at the time they agreed to give samples to the involved biobank. Those with disseminated disease before surgery were excluded. Demographic and clinical data including complications within 30 days were extracted from the Swedish ColoRectal Cancer Registry (SCRCR)7. The study compared patients with peritoneal infection (anastomotic leak and/or intra-abdominal abscess within 30 days) with controls who had a complication-free postoperative course. Case and control status were verified by chart review. Cases and controls were matched 1:1 according to: operating hospital (Uppsala or Umeå), tumour location (colon or rectum), pathological tumour stage (pTNM I, II or III), age (±5 years at the index operation) and sex (male/female).

Preoperative whole-blood samples were requested from the Uppsala-Umeå Cancer Consortium biobank (U-CAN)8. These samples were sent to the National Genomics Infrastructure Science for Life Laboratory, Uppsala, Sweden, for genotyping using the Illumina Infinium assay and GenomeStudio 2.0.3.

Frequencies of the allele compositions of the COX-2 gene promoter −765G > C were tabulated. The association between allelic combinations and peritoneal infection was evaluated with logistic regression for additive effects. Quality control and statistical analysis were performed with Plink v.1.99.

A protein quantitative trait loci analysis (pQTL) was also performed, including 266 proteins and 547 294 variants (see Supplementary Methods).

Results

Forty-seven patients with peritoneal infection were matched with 47 controls with a complication-free postoperative course (Fig. S1). A higher ASA score, higher BMI and neoadjuvant therapy were more frequent among patients with peritoneal infection (Table 1).

Table 1

Clinical data for 94 colorectal cancer patients

VariablesPeritoneal infection
Complication-free (n = 47)Infected (n = 47)
Age (years), median (i.q.r.)70 (63–76)69 (62–77)
Sex
 Male26 (55.3)26 (55.3)
 Female21 (44.7)21 (44.7)
ASA fitness grade
 ASA I–II40 (85.1)34 (72.3)
 ASA III7 (14.9)12 (25.5)
 Missing0 (0.0)1 (2.1)
BMI (kg/m2)
 <2522 (46.8)17 (36.2)
 25–3018 (38.3)19 (40.4)
 >307 (14.9)11 (23.4)
Tumour location
 Colon25 (53.2)25 (53.2)
 Rectum22 (46.8)22 (46.8)
Neoadjuvant treatment
 No34 (72.3)27 (57.4)
 Radiotherapy7 (14.9)11 (23.4)
 Chemoradiotherapy6 (12.8)9 (19.1)
Diverting stoma
 No29 (61.7)27 (57.4)
 Yes18 (38.3)20 (42.6)
Intraoperative blood loss (ml), median (i.q.r.)100 (50–300)200 (100–500)
Surgical approach
 Open38 (80.9)35 (74.5)
 Laparoscopic7 (14.9)10 (21.3)
 Conversion to open2 (4.3)2 (4.3)
Year of surgery2013 (2012–2014)2013 (2012–2015)
pTNM
 I11 (23.4)11 (23.4)
 II20 (42.6)20 (42.6)
 III16 (34.0)16 (34.0)
VariablesPeritoneal infection
Complication-free (n = 47)Infected (n = 47)
Age (years), median (i.q.r.)70 (63–76)69 (62–77)
Sex
 Male26 (55.3)26 (55.3)
 Female21 (44.7)21 (44.7)
ASA fitness grade
 ASA I–II40 (85.1)34 (72.3)
 ASA III7 (14.9)12 (25.5)
 Missing0 (0.0)1 (2.1)
BMI (kg/m2)
 <2522 (46.8)17 (36.2)
 25–3018 (38.3)19 (40.4)
 >307 (14.9)11 (23.4)
Tumour location
 Colon25 (53.2)25 (53.2)
 Rectum22 (46.8)22 (46.8)
Neoadjuvant treatment
 No34 (72.3)27 (57.4)
 Radiotherapy7 (14.9)11 (23.4)
 Chemoradiotherapy6 (12.8)9 (19.1)
Diverting stoma
 No29 (61.7)27 (57.4)
 Yes18 (38.3)20 (42.6)
Intraoperative blood loss (ml), median (i.q.r.)100 (50–300)200 (100–500)
Surgical approach
 Open38 (80.9)35 (74.5)
 Laparoscopic7 (14.9)10 (21.3)
 Conversion to open2 (4.3)2 (4.3)
Year of surgery2013 (2012–2014)2013 (2012–2015)
pTNM
 I11 (23.4)11 (23.4)
 II20 (42.6)20 (42.6)
 III16 (34.0)16 (34.0)

Cases with peritoneal infection and complication-free controls. Values are n (%) unless otherwise stated. i.q.r., interquartile range; pTNM, pathological tumour stage.

Table 1

Clinical data for 94 colorectal cancer patients

VariablesPeritoneal infection
Complication-free (n = 47)Infected (n = 47)
Age (years), median (i.q.r.)70 (63–76)69 (62–77)
Sex
 Male26 (55.3)26 (55.3)
 Female21 (44.7)21 (44.7)
ASA fitness grade
 ASA I–II40 (85.1)34 (72.3)
 ASA III7 (14.9)12 (25.5)
 Missing0 (0.0)1 (2.1)
BMI (kg/m2)
 <2522 (46.8)17 (36.2)
 25–3018 (38.3)19 (40.4)
 >307 (14.9)11 (23.4)
Tumour location
 Colon25 (53.2)25 (53.2)
 Rectum22 (46.8)22 (46.8)
Neoadjuvant treatment
 No34 (72.3)27 (57.4)
 Radiotherapy7 (14.9)11 (23.4)
 Chemoradiotherapy6 (12.8)9 (19.1)
Diverting stoma
 No29 (61.7)27 (57.4)
 Yes18 (38.3)20 (42.6)
Intraoperative blood loss (ml), median (i.q.r.)100 (50–300)200 (100–500)
Surgical approach
 Open38 (80.9)35 (74.5)
 Laparoscopic7 (14.9)10 (21.3)
 Conversion to open2 (4.3)2 (4.3)
Year of surgery2013 (2012–2014)2013 (2012–2015)
pTNM
 I11 (23.4)11 (23.4)
 II20 (42.6)20 (42.6)
 III16 (34.0)16 (34.0)
VariablesPeritoneal infection
Complication-free (n = 47)Infected (n = 47)
Age (years), median (i.q.r.)70 (63–76)69 (62–77)
Sex
 Male26 (55.3)26 (55.3)
 Female21 (44.7)21 (44.7)
ASA fitness grade
 ASA I–II40 (85.1)34 (72.3)
 ASA III7 (14.9)12 (25.5)
 Missing0 (0.0)1 (2.1)
BMI (kg/m2)
 <2522 (46.8)17 (36.2)
 25–3018 (38.3)19 (40.4)
 >307 (14.9)11 (23.4)
Tumour location
 Colon25 (53.2)25 (53.2)
 Rectum22 (46.8)22 (46.8)
Neoadjuvant treatment
 No34 (72.3)27 (57.4)
 Radiotherapy7 (14.9)11 (23.4)
 Chemoradiotherapy6 (12.8)9 (19.1)
Diverting stoma
 No29 (61.7)27 (57.4)
 Yes18 (38.3)20 (42.6)
Intraoperative blood loss (ml), median (i.q.r.)100 (50–300)200 (100–500)
Surgical approach
 Open38 (80.9)35 (74.5)
 Laparoscopic7 (14.9)10 (21.3)
 Conversion to open2 (4.3)2 (4.3)
Year of surgery2013 (2012–2014)2013 (2012–2015)
pTNM
 I11 (23.4)11 (23.4)
 II20 (42.6)20 (42.6)
 III16 (34.0)16 (34.0)

Cases with peritoneal infection and complication-free controls. Values are n (%) unless otherwise stated. i.q.r., interquartile range; pTNM, pathological tumour stage.

Only one patient homozygous for the minor allele (that is C/C) was identified in both the case and control group. Ten individuals in the case group and 14 individuals in the control group were heterozygous for the minor allele (that is G/C), whereas 36 individuals in the case group and 32 individuals in the control group were homozygous for the major allele (that is G/G). There were more individuals with heterozygosity in the control group than in the case group (Table 2). The logistic regression model for additive effects testing −765G > C and case/control status demonstrated an odds ratio of 0.71 (P = 0.413).

Table 2

Frequency table of the single-nucleotide polymorphism of the COX-2 gene promoter −765G > C for 94 patients with colorectal cancer undergoing surgical resection, all with a primary anastomosis

Number of patients with specific allelic combinations
Peritoneal infectionG/GG/CC/C
 Infected36101
 Complication-free32141
Number of patients with specific allelic combinations
Peritoneal infectionG/GG/CC/C
 Infected36101
 Complication-free32141

Patients with peritoneal infection versus complication-free controls.

Table 2

Frequency table of the single-nucleotide polymorphism of the COX-2 gene promoter −765G > C for 94 patients with colorectal cancer undergoing surgical resection, all with a primary anastomosis

Number of patients with specific allelic combinations
Peritoneal infectionG/GG/CC/C
 Infected36101
 Complication-free32141
Number of patients with specific allelic combinations
Peritoneal infectionG/GG/CC/C
 Infected36101
 Complication-free32141

Patients with peritoneal infection versus complication-free controls.

The pQTL did not demonstrate any significant findings (see Supplementary material).

Discussion

In this retrospective matched cohort study, the previous findings of Reisinger et al.5 could not be reproduced, in which homozygosity for the polymorphism of the COX-2 gene promoter −765G > C minor allele was associated with peritoneal infection after colorectal cancer resection with an anastomosis. The calculated point estimate demonstrated a non-significant reverse association in the present study.

In the study by Reisinger et al.5, tissue samples from 148 consecutive colorectal cancer patients were collected at a single centre, and all were genotyped for PTGS2-765G > C. Seven patients were homozygous for the polymorphism, and three of them experienced anastomotic leakage, compared with 16 of 141. This corresponds to a leakage frequency of 43% versus 11% and a corresponding odds ratio of 5.86, in stark contrast to the present study.

Possible explanations for these differing results could be that the present study was underpowered, resulting in false negative findings. A notable analytic difference is that all categories of −765G > C were included, while the former study only compared C/C versus the rest (that is G/C and G/G grouped together). In the present study, heterozygotes were included as a separate group in the analyses as previous studies have demonstrated alterations in biological status associated with the minor allele of C even in the heterozygote state6,10.

Another difference between the studies is the outcome definition, as the composite of peritoneal infection (that is anastomotic leakage and/or abscess) was used here, in contrast to anastomotic leakage exclusively. In addition, medical charts of all cases and controls were reviewed to avoid misclassification of case-control status, while classification of anastomotic leakage in the study by Reisinger et al.5 is unclear. Another aspect to consider is adjustment for confounding, which to some degree was performed through matching in this case-control study; this was not adjusted in the former study. Notably, there were also differences in allele frequencies, as the study by Reisinger et al. had 4.7% homozygosity, in comparison to 2.1% in the present report. It was unknown what frequency to expect of the −765G > C variant in this Swedish cohort. The present findings could be valuable for future research, including power calculations.

Regarding the expressional effect of −765G > C, reports are conflicting. An initial hypothesis was that this minor allele would reduce promoter activity and affect COX-2 gene expression levels and function6, while subsequent studies reported conflicting evidence11–13, that is that G/C and C/C can lead to increased production of prostaglandins, displayed in both in vivo and in vitro studies. Moreover, COX-2 expression has been suggested to be important for anastomotic healing5. If the minor allele of −765G/C does not result in a decreased, but rather an increased COX-2 function, this could be in line with these findings of numerically less peritoneal infections in those with a higher frequency of the minor allele.

Funding

Knut and Alice Wallenberg Foundation, Swedish Society of Medicine, Cancer Research Foundation in Northern Sweden.

Disclosure

The authors declare no conflict of interest.

Supplementary material

Supplementary material is available at BJS Open online.

Data availability

The data for this paper will be stored at the Department of Surgical and Perioperative Sciences at Umeå University hospital for 10 years. This data can only be made available with relevant ethical permits due to the sensitive information contained.

Author contributions

Oskar Grahn (Data curation, Formal analysis, Methodology, Project administration, Software, Validation, Visualization, Writing—original draft, Writing—review & editing), Mun-Gwan Hong (Formal analysis, Investigation, Methodology, Software, Writing—review & editing), Klas Holmgren (Data curation, Formal analysis, Writing—review & editing), Malin Sund (Formal analysis, Methodology, Supervision, Writing—review & editing) and Martin Rutegård (Conceptualization, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Writing—review & editing)

References

1

Kube
 
R
,
Mroczkowski
 
P
,
Granowski
 
D
,
Benedix
 
F
,
Sahm
 
M
,
Schmidt
 
U
 et al.  
Anastomotic leakage after colon cancer surgery: a predictor of significant morbidity and hospital mortality, and diminished tumour-free survival
.
Eur J Surg Oncol
 
2010
;
36
:
120
124

2

Boström
 
P
,
Haapamäki
 
MM
,
Rutegård
 
J
,
Matthiessen
 
P
,
Rutegård
 
M
.
Population-based cohort study of the impact on postoperative mortality of anastomotic leakage after anterior resection for rectal cancer
.
BJS Open
 
2019
;
3
:
106
111

3

Grahn
 
O
,
Lundin
 
M
,
Chapman
 
SJ
,
Rutegård
 
J
,
Matthiessen
 
P
,
Rutegård
 
M
.
Postoperative nonsteroidal anti-inflammatory drugs in relation to recurrence, survival and anastomotic leakage after surgery for colorectal cancer
.
Colorectal Dis
 
2022
;
24
:
933
942

4

Cata
 
JP
,
Guerra
 
CE
,
Chang
 
GJ
,
Gottumukkala
 
V
,
Joshi
 
GP
.
Non-steroidal anti-inflammatory drugs in the oncological surgical population: beneficial or harmful? A systematic review of the literature
.
Br J Anaesth
 
2017
;
119
:
750
764

5

Reisinger
 
KW
,
Schellekens
 
DH
,
Bosmans
 
JW
,
Boonen
 
B
,
Hulsewe
 
KW
,
Sastrowijoto
 
P
 et al.  
Cyclooxygenase-2 is essential for colorectal anastomotic healing
.
Ann Surg
 
2017
;
265
:
547
554

6

Papafili
 
A
,
Hill
 
MR
,
Brull
 
DJ
,
McAnulty
 
RJ
,
Marshall
 
RP
,
Humphries
 
SE
 et al.  
Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response
.
Arterioscler Thromb Vasc Biol
 
2002
;
22
:
1631
1636

7

Moberger
 
P
,
Sköldberg
 
F
,
Birgisson
 
H
.
Evaluation of the Swedish colorectal cancer registry: an overview of completeness, timeliness, comparability and validity
.
Acta Oncol
 
2018
;
57
:
1611
1621

8

Glimelius
 
B
,
Melin
 
B
,
Enblad
 
G
,
Alafuzoff
 
I
,
Beskow
 
A
,
Ahlström
 
H
 et al.  
U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden
.
Acta Oncol (Madr)
 
2018
;
57
:
187
194

9

Chang
 
CC
,
Chow
 
CC
,
Tellier
 
LC
,
Vattikuti
 
S
,
Purcell
 
SM
,
Lee
 
JJ
.
Second-generation PLINK: rising to the challenge of larger and richer datasets
.
Gigascience
 
2015
;
4
:
7

10

de Vries
 
HS
,
te Morsche
 
RH
,
van Oijen
 
MG
,
Nagtegaal
 
ID
,
Peters
 
WH
,
de Jong
 
DJ
.
The functional -765G→C polymorphism of the COX-2 gene may reduce the risk of developing Crohn’s disease
.
PLoS One
 
2010
;
5
:
e15011

11

Szczeklik
 
W
,
Sanak
 
M
,
Szczeklik
 
A
.
Functional effects and gender association of COX-2 gene polymorphism G-765C in bronchial asthma
.
J Allergy Clin Immunol
 
2004
;
114
:
248
253

12

Sanak
 
M
,
Szczeklik
 
W
,
Szczeklik
 
A
.
Association of COX-2 gene haplotypes with prostaglandins production in bronchial asthma
.
J Allergy Clin Immunol
 
2005
;
116
:
221
223

13

Sanak
 
M
,
Plutecka
 
H
,
Szczeklik
 
W
,
Piwowarska
 
W
,
Rostoff
 
P
,
Szczeklik
 
A
.
Functional promoter polymorphism of cyclooxygenase-2 modulates the inflammatory response in stable coronary heart disease
.
Pol Arch Med Wewn
 
2010
;
120
:
82
88

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected]

Supplementary data